The recombinant anti-MET/EpCAM bispecific antibody fragment: a promising novel therapeutic approach for breast cancer treatment [0.03%]
重组抗MET/EpCAM双特异性抗体片段：治疗乳腺癌的新型潜在疗法
Roya Mirzaei,Mohammadreza Azimi,Soroush Karimi et al.
Roya Mirzaei et al.
Our study aims to target Met and EpCAM to inhibit angiogenesis in breast cancer, particularly triple-negative breast cancer (TNBC). We have developed a new bispecific antibody that targets both MET and EpCAM, which are commonly overexpresse...
Orelabrutinib combined with rituximab and high-dose methotrexate as induction therapy in newly diagnosed primary central nervous system lymphoma [0.03%]
奥马鲁布替尼联合利妥昔单抗和大剂量甲氨蝶呤作为新诊断中枢神经系统淋巴瘤的一线诱导治疗方案研究
Xi-Bin Xiao,Yi-Qin Weng,Hua-Wei Jiang et al.
Xi-Bin Xiao et al.
Objective: Limited treatment options for primary central nervous system lymphoma (PCNSL) highlight the need for alternative therapies. This study evaluated orelabrutinib (O) and rituximab (R), plus high-dose methotrexate ...
Peptide YY fragment PYY1-36 disrupts mitochondrial biogenesis via RBM43-dependent PGC-1α translation inhibition [0.03%]
肽段PYY1-36通过依赖RBM43的PGC-1α翻译抑制干扰线粒体生物生成
Benkun Liu,Fucheng Zhou,Bowen Shi et al.
Benkun Liu et al.
Mitochondrial dysfunction is a key driver of cancer progression, with therapies increasingly targeting metabolic weaknesses. Peptide YY (PYY), a gastrointestinal hormone, regulates cellular activity, but its influence on mitochondrial healt...
Medulloblastoma associated with Lynch syndrome: a case report of germline MLH1 variant and tumor molecular characterization [0.03%]
与林奇综合征相关的髓母细胞瘤病例报告及肿瘤分子特征研究
Han Zheng,Gang Zhang,Bin Jiang et al.
Han Zheng et al.
Lynch syndrome (LS) is an autosomal autosomal dominant inherited disease characterized by impaired DNA mismatch repair (dMMR), resulting in an elevated susceptibility to various types of cancer. The incidence of brain cancers in individuals...
Abhishesh Kumar Badal,Arnab Nayek,Ruby Dhar et al.
Abhishesh Kumar Badal et al.
Cancer is a major cause of morbidity and mortality, making it one of the most debilitating diseases in our time. Despite advancements in therapeutic strategies, the development of chemoresistance and the occurrence of secondary tumours pose...
Evaluation of anti-leukemic activity and underlying mechanisms of the novel GSPT1 degrader AB138 in acute myeloid leukemia [0.03%]
评估新型GSPT1降解剂AB138在急性髓系白血病中的抗白血病作用及潜在机制
Liqiang Wang,Xin Cai,Yang Kong et al.
Liqiang Wang et al.
Acute myeloid leukemia (AML) is a relapsing and drug-resistant hematologic malignancy. We report AB138, a novel molecular glue degrader that recruits G1-to-S phase transition protein 1 (GSPT1) to cereblon (CRBN). In AML cell lines, AB138 in...
Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors [0.03%]
靶向IL-1受体辅助蛋白单克隆抗体nadunolimab联合帕博利珠单抗治疗实体瘤患者的安全性、耐受性和初步疗效：一项I期临床试验
Roger B Cohen,Antonio Jimeno,Jennifer Hreno et al.
Roger B Cohen et al.
Interleukin (IL)-1 signaling has an essential role in tumor progression and immunosuppression and is linked to acquired resistance to anti-PD-1/PD-L1 treatment. Nadunolimab is an IL1RAP (IL-1 receptor accessory protein)-targeting antibody t...
An investigation of extended-interval dosing of atezolizumab in Japanese patients with advanced solid tumors: safety and pharmacokinetics of a dose of 1680 mg every 4 weeks [0.03%]
阿特珠单抗在日本晚期实体瘤患者中延长给药间隔的Ⅰ期研究：1680mg每4周一次给药的安全性和药代动力学
Shunsuke Kondo,Shigehisa Kitano,Jun Sato et al.
Shunsuke Kondo et al.
In Japan, atezolizumab is indicated for several cancers at a dose of 1200 mg every 3 weeks or 840 mg every 2 weeks. This open-label study (jRCT2031220151) aimed to assess an atezolizumab monotherapy dose of 1680 mg every 4 weeks (Q4W) in Ja...
Targeting Myc through BET-PROTAC elicits potent anti-lymphoma activity in diffuse large B cell lymphoma [0.03%]
靶向MYC的BET-PROTAC在弥漫性大B细胞淋巴瘤中产生强烈的抗淋巴瘤活性
Hui Wang,Ximei Wu,Jingjing Gao et al.
Hui Wang et al.
Diffuse large B cell lymphoma (DLBCL) presents a great challenge in the clinic due to its poor prognosis. Prior research has identified c-Myc as a promising therapeutic target in DLBCL; however, direct targeting of c-Myc protein has proven ...
Novel GPC3 N-terminal bispecific antibody exhibits dual anti-tumor effect against tumor cells [0.03%]
新型GPC3-N端双特异性抗体对肿瘤细胞的双重抗肿瘤作用
Xinsheng Zhou,Yixin Liu,Xuan Liu et al.
Xinsheng Zhou et al.
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with poor prognosis and limited treatment options, particularly in advanced stages. Glypican-3 (GPC3) has emerged as a promising therapeutic targe...